PURPOSE: Metastasis, the main cause of death from cancer, remains poorly understood at the molecular level. EXPERIMENTAL DESIGN: Based on a pattern of reduced expression in human prostate cancer tissues and tumor cell lines, a candidate suppressor gene (SPARCL1) was identified. We used in vitro approaches to determine whether overexpression of SPARCL1 affects cell growth, migration, and invasiveness. We then employed xenograft mouse models to analyze the impact of SPARCL1 on prostate cancer cell growth and metastasis in vivo. RESULTS: SPARCL1 expression did not inhibit tumor cell proliferation in vitro. By contrast, SPARCL1 did suppress tumor cell migration and invasiveness in vitro and tumor metastatic growth in vivo, conferring improved survival in xenograft mouse models. CONCLUSIONS: We present the first in vivo data suggesting that SPARCL1 suppresses metastasis of prostate cancer.
PURPOSE: Metastasis, the main cause of death from cancer, remains poorly understood at the molecular level. EXPERIMENTAL DESIGN: Based on a pattern of reduced expression in humanprostate cancer tissues and tumor cell lines, a candidate suppressor gene (SPARCL1) was identified. We used in vitro approaches to determine whether overexpression of SPARCL1 affects cell growth, migration, and invasiveness. We then employed xenograft mouse models to analyze the impact of SPARCL1 on prostate cancer cell growth and metastasis in vivo. RESULTS:SPARCL1 expression did not inhibit tumor cell proliferation in vitro. By contrast, SPARCL1 did suppress tumor cell migration and invasiveness in vitro and tumor metastatic growth in vivo, conferring improved survival in xenograft mouse models. CONCLUSIONS: We present the first in vivo data suggesting that SPARCL1 suppresses metastasis of prostate cancer.
Keywords:
CaP; GFP-positive PC3-Luc cells expressing empty control vector; GFP-positive PC3-Luc cells overexpressing SPARCL1; Gene expression signature; H.E.; IC; IHC; IVIS; Immunohistochemistry; Intracardiac; Meta-analysis; Metastasis; OX; PC3-Luc; PC3-luc/EV; PC3-luc/SPARCL1; Prostate cancer; SCID; SPARCL1; SPARCL1 function in vivo; Severe combined immunodeficient; cancer of the prostate gland; hematoxylin and eosin; in vivo Imaging System; orthotopic xenografting; secreted protein acidic and rich in cysteine-like 1; the bioluminescent human prostate carcinoma cell line
Authors: Uma R Chandran; Changqing Ma; Rajiv Dhir; Michelle Bisceglia; Maureen Lyons-Weiler; Wenjing Liang; George Michalopoulos; Michael Becich; Federico A Monzon Journal: BMC Cancer Date: 2007-04-12 Impact factor: 4.430
Authors: Paula J Hurley; Luigi Marchionni; Brian W Simons; Ashley E Ross; Sarah B Peskoe; Rebecca M Miller; Nicholas Erho; Ismael A Vergara; Mercedeh Ghadessi; Zhenhua Huang; Bora Gurel; Ben Ho Park; Elai Davicioni; Robert B Jenkins; Elizabeth A Platz; David M Berman; Edward M Schaeffer Journal: Proc Natl Acad Sci U S A Date: 2012-08-27 Impact factor: 11.205
Authors: Paula J Hurley; Robert M Hughes; Brian W Simons; Jessie Huang; Rebecca M Miller; Brian Shinder; Michael C Haffner; David Esopi; Yasunori Kimura; Javaneh Jabbari; Ashley E Ross; Nicholas Erho; Ismael A Vergara; Sheila F Faraj; Elai Davicioni; George J Netto; Srinivasan Yegnasubramanian; Steven S An; Edward M Schaeffer Journal: Cancer Res Date: 2015-08-20 Impact factor: 12.701
Authors: Yuzhu Xiang; Qingchao Qiu; Ming Jiang; Renjie Jin; Brian D Lehmann; Douglas W Strand; Bojana Jovanovic; David J DeGraff; Yi Zheng; Dina A Yousif; Christine Q Simmons; Thomas C Case; Jia Yi; Justin M Cates; John Virostko; Xiusheng He; Xunbo Jin; Simon W Hayward; Robert J Matusik; Alfred L George; Yajun Yi Journal: Mol Oncol Date: 2013-07-20 Impact factor: 6.603
Authors: Brian David Lehmann; Yan Ding; Daniel Joseph Viox; Ming Jiang; Yi Zheng; Wang Liao; Xi Chen; Wei Xiang; Yajun Yi Journal: BMC Cancer Date: 2015-03-26 Impact factor: 4.430